Objectives: To evaluate the effect of Candida albicans mitochondrial respiratory status on antifungal azole susceptibility.
Introduction
Infections caused by the opportunistic human pathogen Candida albicans have increased dramatically in recent decades due to the rapid rise in the number of immunocompromised patients. The triazole fluconazole is the most widely used antifungal drug in the treatment of Candida infections. Unfortunately, the rapid emergence of azole resistance is a major problem in successful chemotherapy. 1 Studies suggest that multifactorial and multistep alterations give rise to antifungal resistance in C. albicans. The main mechanisms of azole resistance include a defective Erg3 function generating changed membrane sterol content, 2 overexpression of the gene encoding the target of the azoles, lanosterol demethylase (ERG11), 3 mutations in ERG11, 4, 5 reduced intracellular drug accumulation due to the overexpression of genes that encode membrane transport proteins such as energy-dependent ATP-binding cassette transporters (e.g. CDR1 and CDR2) and/or the proton motive force-dependent major facilitators superfamily (e.g. MDR1), 6 -8 as well as biofilm formation. 9 Overexpression of ERG11 has been shown to be controlled by a gain-of-function mutation in the transcription factor gene UPC2, 10 while overexpression of CDR1 and CDR2 is due to similar mutations in both TAC1 alleles, 11, 12 and constitutive MDR1 overexpression is due to hyperactivating mutations in MRR1. 13 More recently, it has been widely accepted that C. albicans can exploit several cellular responses to facilitate resistance to antifungal agents and can further acquire resistance by multiple mechanisms. 1, 14 Both the calcium -calmodulin -calcineurin pathway 15 and the cAMP protein kinase A pathway 16 are found to contribute significantly to modulation of fluconazole tolerance in C. albicans in response to antifungal stress. We previously presented evidence that a protective metabolic shift due to mitochondrial respiration deficiency may enable the fluconazole-resistant C. albicans strain to survive drug challenge partly due to a reduction in the generation of intracellular reactive oxygen species (ROS). 17 Furthermore, several studies have also demonstrated that metabolic adaptability is a mechanism by which C. albicans cells respond to a stressful host environments. 18 -20 As a result, it is expected that mitochondrial functions that regulate metabolic behaviour are likely to contribute to fitness and flexibility of C. albicans strains in response to external challenges.
Despite the fact that mitochondrial DNA deficiency or mitochondrial respiration blockage leads to decreased susceptibility to azoles in both Saccharomyces cerevisiae 21 and Candida glabrata, 22, 23 and that inhibition of the Candida parapsilosis mitochondrial respiratory pathway enhances susceptibility to caspofungin, 24 the relationship between mitochondrial respiration status and drug susceptibility in C. albicans is still poorly understood. A respiratory-deficient mutant of C. albicans (MMU11) generated by culturing with ethidium bromide is tolerant to amphotericin B, but this mutant strain has not been used to explore its susceptibility to azoles. 25 More recently, the P5 petite mutant of C. albicans in which oxidative phosphorylation is uncoupled was shown to exhibit diminished susceptibility to fluconazole most probably through increased drug efflux due to MDR1 overexpression, while it was not found to change its susceptibility to amphotericin B. 26 These studies suggest that there is a complex link between mitochondrial function and antifungal resistance in C. albicans. The present study was therefore conducted to explore the antifungal susceptibility of C. albicans under conditions of mitochondrial respiration blockage.
Bioenergetic studies have found that there are three specific respiratory pathways present in C. albicans: the classical respiratory chain (CRC), the alternative respiratory chain and the parallel electron transport chain (PAR). 27 -29 As is also observed in mammalian cells, the CRC of C. albicans comprises four enzyme complexes and is inhibited in the presence of cyanide or antimycin A. 28 In C. albicans, the alternative respiratory pathway is generally conferred by a cyanide-insensitive alternative oxidase (Aox) located on the matrix side of the inner mitochondrial membrane and encoded by two nuclear genes, AOX1a and AOX1b. The constitutive Aox1a or the inducible Aox1b bypass the CRC by transferring electrons directly from ubiquinol to oxygen. 30, 31 Aox1b is induced by cyanide and oxidants such as hydrogen peroxide (H 2 O 2 ), menadione and paraquat. 31 This alternative respiratory pathway is inhibited in the presence of salicylhydroxamic acid (SHAM). 28 Finally, the PAR is only efficient when both the CRC and Aox pathways are blocked, allowing electron flux to be redirected upstream of complex III, in parallel to CRC. 29 In this study, we asked whether cyanide or SHAM might modify antifungal susceptibility in C. albicans. We then concentrated on Aox function in fluconazole susceptibility as the alternative respiration pathway decreased susceptibility to azole agents. To test the idea that blockage of Aox function might enhance azole antifungal susceptibility, we further assessed the in vitro combination of fluconazole and SHAM against several clinical C. albicans isolates.
Materials and methods

Agents
Standard antifungal powders of fluconazole, ketoconazole, itraconazole, miconazole, terbinafine, amphotericin B and methyl-1-(butylcarbamoyl)-2-benz-imidazolecarbamate (benomyl) were obtained from Sigma (St Louis, MO, USA). Stock solutions were prepared in distilled water for fluconazole and in DMSO for ketoconazole, itraconazole, miconazole, terbinafine, amphotericin B and benomyl, then filter sterilized and stored at -708C. Stock solutions of SHAM (200 mM; Sigma) and potassium cyanide (KCN; 1 M; Sinopharm Chemical Reagent Co. Ltd, PR China) were prepared in 95% ethanol and in distilled water, respectively.
Organism and media C. albicans strains used in this study are listed in Table 1 32 isogenic aox1a/aox1a mutant strain WH304, aox1b/aox1b mutant strain WH314, aox1a/aox1a aox1b/aox1b double mutant strain WH324, AOX1a overexpression strain WH342 and AOX1b overexpression strain WH343 were described previously. 30, 31 Twenty clinical isolates of fluconazole-susceptible and -resistant C. albicans were obtained from Changhai Hospital Strains Collection Center (Shanghai, PR China).
Cultures were routinely inoculated from single colonies of each strain in GLC broth (10 g of yeast extract, 20 g of peptone, 10 g of dextrose and 10 g of glycerol per litre) and grown at 308C in a shaking (200 rpm) incubator. All aox mutants and the WT strain were maintained at 308C in yeast nitrogen base (YNB; Difco, Detroit, MI, USA) broth containing 2% glucose and 50 mg/L uridine. For mitochondrial respiration blockage, the overnight cultures were subcultured onto GLC agar plates (10 g of yeast extract, 20 g of peptone, 10 g of dextrose, 10 g of glycerol and 18 g of agar per litre) in the presence of 1 mM KCN or 5 mM SHAM.
Antifungal susceptibility testing
Spot assay. C. albicans strains in mid-logarithmic phase were collected by centrifugation at 3000 g for 5 min, counted, and resuspended in 0.9% sterile normal saline at a concentration of 10 7 cells/mL; 5 mL of these cultures was spotted in serial 10-fold dilutions on drug-containing GLC agar plates (fluconazole, 64 mg/L; itraconazole, 4 mg/L; ketoconazole, 8 mg/L; miconazole, 16 mg/L). 34 To determine drug susceptibility in the presence of respiratory inhibitors, plates were supplemented with 1 mM KCN or 5 mM SHAM. Cell viability was assessed by colony formation after 48 h incubation at 308C.
Agarose disc diffusion method. C. albicans cells in mid-logarithmic phase were collected and resuspended as described above. A total of 5 mL of the cell suspensions (10 5 cells/mL) was deposited onto the 100 mm GLC agar plates. Excess fluid was removed after 1 h incubation at 308C, and the plates were dried for 30 min. Filter discs were placed on the plates and then the antifungal drugs, in volumes of 5 mL, were spotted onto the discs in the indicated amounts: fluconazole, 10 or 20 mg; itraconazole, 8 mg; ketoconazole, 8 mg; miconazole, 10 mg; terbinafine, 40 mg; amphotericin B, 8 mg. 22, 34, 35 There was 5 mL of DMSO on the control discs. For characterization of the drug susceptibility of strains in the presence of respiration inhibitors, plates were supplemented with 1 mM KCN or 5 mM SHAM in advance. The same volume of 95% ethanol as that of 5 mM SHAM was in the control agar plates. To determine the effectiveness of the fluconazole-SHAM combination, discs were impregnated with fluconazole and SHAM alone or in combination. The same volume of 95% ethanol as that of the SHAM application was in the control discs. Inhibition zones were scored after incubation at 308C for 48 h.
Chequerboard microdilution assay. Assays were performed on all 20 clinical isolates according to methods of the CLSI (formerly NCCLS) (M27-A). 36 The initial density of fungal suspension in RPMI 1640 medium (American Bioorganics, Niagara Falls, NY, USA) was 0.5-2.5Â10 3 cells/mL, and the final concentrations ranged from 0.125 to 64 mg/L or from 0.016 to 8 mg/L for fluconazole and from 1 to 20 mM for SHAM. Optical density was measured at 630 nm after incubation for 24 h at 308C. The MIC 80 was determined as the lowest concentration of the drugs (alone or in combination) that inhibited growth by 80%, compared with that of the drug-free wells. The fractional inhibitory concentration (FIC) index was defined as the sum of the MIC 80 of each drug when used in combination divided by the MIC of the drug used alone. Synergy and antagonism were defined by FIC indices of 0.5 and .4, respectively. An FIC index result of .0.5 but 4 was considered as no interaction.
After the MIC 80 s were measured, a sample of 100 mL from each well of the microtitre plate was transferred to GLC agar plates. The cfu were counted after incubation at 308C for 48 h. The D log cfu was the logarithm value of cfu after 24 h of exposure subtracted from that of cfu at time zero.
Induction of fluconazole resistance
The strategy was performed as previously reported with some modifications. 17 A single colony of C. albicans strain was first inoculated into 10 mL of yeast nitrogen base (YNB) broth and incubated overnight at 308C at 200 rpm. An aliquot of the culture containing 10 6 cells was then transferred to 10 mL of YNB broth containing 64 mg/L fluconazole, and was incubated as described above. At each passage, the broth microdilution method for in vitro antifungal susceptibility testing of C. albicans was performed as a standard method.
36
Measurement of endogenous ROS production ROS production was measured as reported before. 17 In brief, C. albicans strains (1Â10 7 cells/mL) were incubated with 20 mg/L of 2,7-dichlorofluorescin diacetate (DCFH-DA; Molecular Probes) for 30 min at 308C. After being washed and resuspended in phosphate-buffered saline (PBS; 10 mM phosphate buffer, 2.7 mM potassium chloride, 140 mM sodium chloride, pH 7.4), cells were treated with miconazole (12.5 mg/L) and benomyl (50 mg/L) separately at the indicated time. Control groups were treated with PBS containing a volume of DMSO equal to that added to the experimental sample. Fluorescence intensity (FI) values were detected on the POLARstar Galaxy (BMG, Labtech, Offenburg, Germany) with an excitation wavelength at 488 nm and an emission wavelength at 525 nm. ROS production was calculated by subtracting the FI value of cells treated with antifungal agents alone from that of cells treated with antifungal agents in the presence of DCFH-DA.
Statistics
All the experiments were performed at least three times. Data were presented as the mean+SD, and analysed using the Student's t-test where indicated. A P value ,0.05 was considered significant.
Results
Induction of cyanide-insensitive respiration in C. albicans conferred reduced azole susceptibility
In order to investigate whether cyanide would affect drug susceptibility in C. albicans, we used spot and filter disc assays to test two matched pairs of fluconazole-susceptible and -resistant strains. A concentration of 1 mM KCN was used to inhibit cytochrome c oxidase (complex IV) of the CRC pathway and to induce the cyanide-insensitive respiratory pathway in C. albicans, as demonstrated earlier. 27, 28 As shown in the spot assay in Figure 1 , the addition of 1 mM KCN to the culture medium resulted in decreased susceptibility to fluconazole, itraconazole, ketoconazole and miconazole in all four C. albicans strains. The drug susceptibility was further confirmed for these strains by the filter disc method, where the diameters of the inhibition zones of fluconazole, itraconazole, ketoconazole and miconazole discs were decreased in the presence of 1 mM KCN (Figure 2a and b) . However, in contrast to the azoles, terbinafine susceptibility was decreased in strains SC5314 S and SC5314 R , whereas the susceptibility to terbinafine was increased in isolates 1 and 17. In addition, no major difference in the amphotericin B susceptibility of the four strains was evident with the addition of KCN. These results suggest that blocking the classical respiratory pathway with cyanide leads to induction of cyanide-insensitive respiration with a concomitant increase in azole resistance.
Inhibition of SHAM-sensitive respiration in C. albicans enhanced azole susceptibility
As cyanide-insensitive respiration conferred by the protein Aox in C. albicans resulted in decreased susceptibility to azoles, we addressed whether the inhibition of Aox with SHAM would increase azole susceptibility. As expected, all four strains were strikingly susceptible to the azoles tested in the presence of 5 mM SHAM, with larger inhibition zones than those in the absence of SHAM (Figure 2a and b) . In addition, terbinafine susceptibility was also increased for these strains, whereas the addition of SHAM to the culture did not significantly modify amphotericin B susceptibility. These findings obtained with the induction and inhibition of Aox suggest that in C. albicans the alternative cyanide-insensitive pathway contributes to azole resistance.
AOX1b in C. albicans played a major role in conferring reduced azole susceptibility
The Aox protein in C. albicans is encoded by both AOX1a and AOX1b. While AOX1a is expressed constitutively at low levels, AOX1b expression can be induced by respiratory inhibitors and oxidants. 30, 31 To evaluate possible differences in reducing susceptibility to azoles between Aox1a and Aox1b, we compared azole susceptibility of four strains, the WT strain (CAI4), the isogenetic aox1a/aox1a mutant strain (WH304), the aox1b/ aox1b mutant strain (WH314) and the aox1a/aox1a aox1b/ aox1b double mutant strain (WH324). We first examined the growth rate of these strains in GLC broth medium. The generation times of CAI4, WH304, WH314 and WH324 in their exponential phase were 120, 114, 108 and 102 min, respectively, suggesting that the aox mutants and the WT had comparable growth rates. The MIC 80 s of fluconazole, itraconazole, ketoconazole and miconazole for each strain were 0.25, 0.015, 0.015 and 0.045 mg/L, respectively, indicating that the susceptibility of isogenic aox mutants to antifungal azoles was similar to that of the WT strain.
As shown in Figure 2(c) , upon the addition of 1 mM KCN, the strains WT, WH304 and WH314 yielded less clear inhibition zones, with resistant colonies distributed within the inhibition zones. Among them, the inhibition zones of azole discs for the strains WT and WH304 with the induction of Aox1b became less clear and even disappeared, showing resistance to all azoles tested. On the other hand, the inhibition zones of azole discs for the strain WH314 with the induction of Aox1a were relatively clear, when compared with those of the strains WT and WH304, indicating that the degree of reduced susceptibility to azoles for strain WH314 was less evident. Notably, the inhibition zones of azole discs for strain WH324, which lacks all Aox function, were significantly enlarged in the presence of 1 mM KCN, when the PAR pathway is potentially the only active pathway available for respiration. In contrast, the addition of 5 mM SHAM to direct the inhibition of Aox function dramatically increased susceptibility to azoles for the WT, WH304 and WH314 strains when compared with the absence of SHAM, as was evident with the magnified inhibition zones. Since both AOX1a and AOX1b were disrupted in the strain WH324, there was no efficient influence of SHAM on its respiration chain, and thus no evident change in azole susceptibility. These data suggested that AOX1b in C. albicans played a major role in conferring resistance to azole antifungals. It was therefore of interest to examine how the Aox protein functioned in conferring reduced azole susceptibility.
Aox lowered endogenous ROS formation in C. albicans
It has been recently noted that the Aox in plant cells plays a role in the limitation of mitochondrial ROS production. 37 We thus sought to test whether this was true in C. albicans. Alteration of ROS production as measured through DCFH-DA fluorescence over time is shown in Figure 3 . Without exposure to antifungal agents, there was no significant difference in the amount of endogenous ROS generation between the WT, isogenic aox mutant strains and the AOX overexpression strains at each time point. With the treatment of the ROS-inducing agents miconazole and benomyl, ROS generation was augmented in the strains WH304, WH314 and WH324 to a greater degree than in the WT CAI4 (Figure 3a and b) , while in strains WH342 and WH343 the augmentation was less than that in the parental CAI4 (Figure 3c and d) (P,0.05). This inverse relationship between the Aox abundance and the intracellular ROS level indicated that the alternative respiratory pathway might serve to keep endogenous ROS production low in C. albicans, leading to reduced susceptibility to fluconazole.
Aox slowed down the rapid development of fluconazole resistance in C. albicans
Since intracellular ROS is involved in the mechanisms of azole antifungal agents, 38 and Aox lowered intracellular ROS formation as presented above, we asked whether Aox affected the development of fluconazole resistance after long-term fluconazole exposure. The aox mutant strains and the WT strain, which were similarly susceptible to fluconazole, were cultured in medium containing fluconazole at a concentration of 64 mg/L. After 35 passages of drug treatment, all the strains developed distinct degrees of decreased susceptibility to fluconazole. As shown in Table 2 , the MIC 80 s for CAI4, WH304, WH314 and WH324 rose from 0.25 to 16, .64, .64 and .64 mg/L, respectively; all three aox mutant strains developed fluconazole resistance in which there was a .256-fold increase in the MIC 80 s, while the MIC 80 of WT CAI4 was increased only 64-fold. It took longer to develop an equivalent level of reduced susceptibility to fluconazole for CAI4 than for the aox mutant strains.
The difference in the development of fluconazole resistance among the C. albicans strains observed by the broth microdilution method was confirmed by the filter disc assay (Figure 4) . After eight passages of fluconazole exposure, WH324 yielded less clear and smaller inhibition zones for the tested drugs than did WH314, WH304 and CAI4, showing resistance to the drugs. At passage 30, strains WH324, WH314 and WH304 were dramatically resistant to the azole drugs, with resistant colonies distributed within the inhibition zones and some even growing in direct contact with the antifungal discs, while CAI4 was less resistant than the aox mutant strains, with relatively clear inhibition zones. The key results shown were that Aox slowed down the rapid development of fluconazole resistance in C. albicans after long-term fluconazole treatment.
Use of fluconazole-SHAM combination yielded increased fluconazole efficacy
Because C. albicans strains showed increased susceptibility to antifungal azoles with treatment with 5 mM SHAM, we explored the in vitro combined use of fluconazole and SHAM against clinical C. albicans isolates. As summarized in Table 3 , the addition of SHAM remarkably reduced the MIC 80 s of fluconazole, as was evident from the chequerboard analysis. Fluconazole MIC 80 s against resistant isolates decreased .128-fold, and the MIC 80 s against susceptible isolates decreased by 16-to 25-fold. Among the 20 isolates, synergy was observed in 17 (85%), and no interaction was observed in 3 (15%) susceptible isolates.
The filter disc method further demonstrated the synergism between fluconazole and SHAM ( Figure 5 ). Used independently, SHAM had no antifungal activity even at a concentration of 10 mM; fluconazole at 5 mg showed a weak inhibition zone for susceptible isolate 1 and no inhibition for resistant isolate 17. In contrast, when combined with different amounts of SHAM (2, 4, 5, 6, 8 and 10 mM), 5 mg of fluconazole yielded evident and larger inhibition zones. Notably, the combination of 5 mg fluconazole with 5 or 6 mM SHAM caused the greatest inhibition of both isolates 1 and 17.
To establish further whether the fluconazole -SHAM interaction had fungicidal activity, we used cell broth in the wells of microtitre plates after the MIC 80 s were measured. Figure 6 depicts the relationship between the alteration in viable C. albicans cell counts and fluconazole concentration when fluconazole was employed with or without SHAM. Two typical concentrations of SHAM were selected. We noted 99% or more reduction in viability of both SC5314 S and SC5314 R after 24 h of treatment of fluconazole at concentrations .8 mg/L with the addition of 10 mM SHAM. Specifically, whereas fluconazole had only fungistatic activity, fluconazole combined with 5 or 10 mM SHAM exhibited fungicidal activity at concentrations of 2 and 1 mg/L, respectively, against SC5314 S (Figure 6a ). It was noteworthy that the addition of 5 mM SHAM dramatically enhanced the fungistatic activity of fluconazole at 0.25 mg/L, and enabled the fungicidal activity at 1.0 mg/L against SC5314 R , the fluconazole MIC 80 of which was .64 mg/L (Figure 6b ). Together these results showed that the combined use of fluconazole and SHAM in vitro produced a synergy against C. albicans strains, particularly against fluconazoleresistant strains.
Discussion
Recent studies have characterized features that distinguish fluconazole-resistant C. albicans strains from fluconazolesusceptible strains, and have revealed a metabolic switch mechanism, mitochondrial respiration deficiency and increased glycolysis as contributing to the survival of C. albicans after long-term antifungal azole treatment and thus their emergence as a drug-resistant population. 17 Yet despite the importance of mitochondria in regulation of energy metabolism, virtually nothing is known about the relationship between the mitochondrial respiratory function and drug susceptibility in C. albicans. Our present study indicated that alternative, cyanide-insensitive, respiration in C. albicans led to decreased fluconazole susceptibility. This is a novel mechanism contributing to azole resistance and increased survival of C. albicans.
It has been well established that inhibition by cyanide or SHAM does not modify electron transport in all the respiratory pathways in C. albicans cells, 28 so we tested drug susceptibility of CRC and the alternative pathway separately with the corresponding inhibitors of respiratory chain function. Interestingly, the induction of the alternative pathway by addition of KCN caused decreased susceptibility to antifungal azoles in both laboratory and clinical C. albicans isolates, in contrast to the inhibition of the alternative respiratory chain by SHAM leading to increased azole susceptibility. Our results were in contrast to those of Helmerhorst et al. 27 This group pre-treated C. albicans cells with or without antimycin A to induce Aox activity, but then examined drug susceptibility on agar plates in the absence of respiratory inhibitors, and found no difference in susceptibility between C. albicans cells pre-treated or not with antimycin A. They concluded that respiration via the alternative pathway did not reduce the susceptibility of C. albicans cells to antifungal drugs, although electron transport through either the conventional or the alternative pathway in the absence of inhibitors in C. albicans cannot be estimated. 28 We suggest the data presented in the current study represent a more accurate picture because the respiratory inhibition was maintained for the duration of the experiment. Generally, C. albicans can activate its alternative respiratory chain in response to ageing, several stress situations such as the presence of H 2 O 2 and superoxide (induced by menadione or paraquats), and the disruption downstream from coenzyme Q of the conventional electron transport chain. 28, 30, 31 Since the induction of intracellular ROS is one of the fungistatic mechanisms of azole antifungal agents, 38 it was expected that the Aox in C. albicans would be induced upon treatment with azoles. Our previous study revealed that AOX1b was upregulated in the laboratory C. albicans strain that developed fluconazole resistance through long-term exposure to inhibitory concentrations of fluconazole. 39 Thus, it can be hypothesized that the excessive ROS generation within the mitochondria caused by azoles might induce Aox, which identified potential important signals linking mitochondrial status to the expression of a nuclear gene AOX encoding the mitochondrial Aox protein. A clinically important mechanism of in vivo tolerance or resistance to azoles could be the activation of the Aox pathway in response to ROS generated by the antifungal azoles and by neutrophils and macrophages during antifungal defence.
The function of Aox in C. albicans remains unclear. In plant species, the alternative pathway is comprised of a single Aox protein and serves to keep mitochondrial ROS low. 37 Our observation that no evident difference existed in intracellular ROS generation between the aox mutant strains and the WT strain without antifungal treatment was consistent with the results of Huh and Kang 31 However, when treated with antifungal agents, the inverse relationship between the abundance of Aox within the mitochondria and the ROS levels was dramatic, suggesting that the inducible activation of Aox1b in C. albicans functioned as an 'electron overflow' to avoid ROS damage in response to antifungal drugs, while constitutively expressed Aox1a might function in a less efficient way under physiological conditions. Our data suggest that Aox in C. albicans might act as a enzyme decreasing the formation of mitochondrial ROS. Nevertheless, it is plausible that activation of Aox may also activate a general stress response pathway. Thus the observed decrease in ROS production could be a side effect of activation of other regulatory pathways.
Exposure of C. albicans cells to antifungal agents induces an immediate stress response, which leads to drug tolerance and is important because it may allow C. albicans to develop highlevel resistance mechanisms that could also confer a fitness gain.
14 Whereas the Aox conferred reduced susceptibility to antifungal azoles in C. albicans, the alternative pathway might contribute to slowing down the development of fluconazole resistance after long-term fluconazole treatment. This argument was supported by the fact that it took a shorter time to develop an equivalent level of fluconazole resistance for the aox mutants than for the WT strain. As appreciated recently, ROS can serve as molecules in signal transduction pathways under subtoxic conditions. 40 Likewise, H 2 O 2 , one type of ROS that has been previously implicated in cellular responses involved in the development of antifungal resistance in C. albicans, modulates the positive regulation between the trans-acting factor (Candida AP-1 protein, Cap1p) and the cis-acting element of the multidrug resistance 1 (MDR1) gene. 41 We assumed that exposure of C. albicans to antifungal azoles induced the efflux of excessive mitochondrial ROS by Aox, which led to the decrease of intracellular H 2 O 2 ; consequentially, after a long-term exposure to fluconazole, the trans-acting role of Cap1p in the H 2 O 2 -dependent transcription of MDR1 was somewhat diminished, slowing down the development of fluconazole resistance.
As noted above, azoles are fungistatic, and resistance to these drugs frequently develops. We observed that SHAM acted synergistically with fluconazole, and that fluconazole became fungicidal against C. albicans when combined with SHAM, especially when used against fluconazole-resistant strains. We thus propose a new approach to chemosensitizing C. albicans cells to the antifungal azoles. To be an effective azole chemosensitizer, SHAM should be specific for the Aox in C. albicans and thus not adversely affect human proteins. Furthermore, SHAM is poorly water soluble and the effective dosage is relatively high. This, along with the results of the analysis of development of fluconazole resistance, still suggested that the effective use of SHAM might not last long in light of the rapid development of resistance. Therefore, the clinical significance of combined use of fluconazole and SHAM requires further investigation through modifications of SHAM.
In summary, the findings described in the present study showed that the Aox conferred reduced susceptibility to antifungal azoles in C. albicans through a potential mechanism that involved decreased intracellular generation of ROS during exposure to antifungal agents. Although the physiological significance of the Aox in C. albicans remains to be elucidated and deserves further investigation, this study focused on the relationship between the Aox and fluconazole susceptibility in C. albicans. We propose that the alternative pathway be considered a new mechanism by which C. albicans strains can protect themselves from antifungal agents. Furthermore, we suggest the application of SHAM as a novel azole chemosensitizer in the treatment of Candida infections, especially of infections with fluconazole-resistant C. albicans strains.
